You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》中金升信達生物(01801.HK)目標價至69元 IBI363腸癌數據勝預期
阿思達克 05-27 10:37
中金上週五(23日)發表研究報告指,信達生物(01801.HK)在ASCO會議上讀出多個重要數據,包括7項口頭報告,其中IBI363(PD-1/IL-2)讀出的黑色素瘤、腸癌、非小細胞肺癌概念驗證(PoC)數據引人注目。 該行表示,信達生物這次首次披露的OS數據仍較大超出預期,IBI363未來有潛力成爲該領域的重磅品種。該行又認爲IBI363在傳統PD-(L)1治療進展的NSCLC,尤其是鱗狀細胞癌中競爭力持續展現。 該行維持信達生物今明兩年的純利預測4.72億及12.98億元人民幣,續予「跑贏行業」評級。另外,考慮到IBI363腸癌數據勝於預期,上調目標價4.5%至69元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account